RecruitingPhase 1NCT06556394

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ractigen Therapeutics.
Intervention
RAG-17(drug)
Enrollment
32 enrolled
Eligibility
18 years · All sexes
Timeline
20242026

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06556394 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials